Keros Therapeutics

Keros Therapeutics: A leader in understanding the role of the Transforming Growth Factor-Beta family of proteins that is a master regulator of red blood cell and platelet production as well as the growth, repair and maintenance of muscle and bone. Lead protein therapeutic product candidate, KER-050, is being developed for the treatment of cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome (MDS) and myelofibrosis, with additional data from Part 1 of Ph 2 study in MDS being presented at ASH 2021. Lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva.
Based in...
US - New England
Clinical Stage
Phase l or ll
Disease Space
Hematology, Metabolic Disorders, Oncology, Rare Disease
Public, USA
Market Cap
500MM - 1B
99 Hayden Avenue
Suite 120 (Building E)
Lexington, MA 02421
United States

Company Participants at Solebury Trout Virtual Management Access Event 2021

Jasbir Seehra
Keros Therapeutics, CEO
Dr. Jasbir Seehra is the Founder and serves as Chief Executive Officer, President & Board Member at Keros Therapeutics. He also served as the Chief Scientific Officer at Ember Therapeutics. He joined Ember as chief scientific officer in 2012; and served on the scientific advisory board since the company was founded. Dr. Seehra is formerly the chief scientific officer of Acceleron Pharma, Inc., which he co-founded in 2003. Dr. Seehra has more than 25 years of experience in drug discovery, including having served as vice president of biological chemistry at Wyeth and a drug discovery consultant to AVEO Pharmaceuticals, Inc. Prior to that, he led the small molecule lead discovery effort at Genetics Institute, Inc. where he started as a bench scientist and held numerous positions with increasing responsibility. At Genetics Institute, Dr. Seehra successfully built the institute's small molecule drug discovery capabilities, including medicinal chemistry, high throughput screening and structural biology. Dr. Seehra has authored numerous publications and is an inventor on 33 patents. Dr. Seehra received his B.S. and Ph.D. in biochemistry from the University of Southampton in England. He completed his postdoctoral work at the Massachusetts Institute of Technology.
Keith Regnante
Keros Therapeutics, CFO
Keith Regnante has served as our Chief Financial Officer since February 2020. Prior to joining us, from August 2016 to January 2020, Mr. Regnante served as Chief Financial Officer at Wave Life Sciences Ltd. From February 2014 to August 2016, Mr. Regnante served as Vice President of Finance at Shire Pharmaceuticals, or Shire, a global biopharmaceutical company. Mr. Regnante also served on the Financial Leadership Team and the R&D Leadership Team while he was at Shire. From September 2013 to February 2014, he served as Head of R&D Finance for ARIAD Pharmaceuticals, Inc. From January 1999 to August 2013, Mr. Regnante held multiple finance positions at Biogen Inc., including Senior Director of Corporate Finance from 2011 to 2013, Senior Director of Worldwide R&D Finance from 2008 to 2011 and several other positions dating back to 1999. Prior to joining finance organizations for biotechnology companies, Mr. Regnante worked as a consultant at The Boston Consulting Group. He holds a B.A. in Economics from Tufts University and an M.B.A. from the MIT Sloan School of Management.

Top 10 Holders of Keros Therapeutics, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Fidelity Management & Research Co. LLC 13.65 3,184,861 147.46 13F 9/30/21
OrbiMed Advisors LLC 7.20 1,679,417 77.76 13F 9/30/21
Deep Track Capital LP 5.51 1,288,724 59.67 Stakes 12/29/21
The Vanguard Group, Inc. 4.80 1,122,555 51.97 Funds 12/31/21
Nantahala Capital Management LLC 3.26 760,383 35.21 13F 9/30/21
State Street Corp. 2.90 677,268 31.36 13F 9/30/21
Vanguard Group, Inc. (Subfiler) 2.87 670,282 31.03 13F 9/30/21
BlackRock Fund Advisors 2.81 654,968 30.33 13F 9/30/21
Alkeon Capital Management LLC (13F Subfiler) 2.57 600,187 27.79 13F 9/30/21
OrbiMed Advisors Private Equity 1.75 406,669 18.83 Funds 3/31/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.